What you should know:
– Hi GreyMatters (GMH), a company dedicated to changing mental health care standards with biomarker-based therapies, starting with PTSD, raises $ 10 million in the Series A funding round led by Otsuka Medical Devices Co., Ltd., with a total funding of $ 13.5 million. Additional investors in the Series A round included Joy Ventures, J-Ventures and J-Impact. Existing GMH investors Marius Nacht and Joyance Ventures also took part in the round.
– GMH develops digital self-neuromodulation therapies for mental disorders to help patients regain action on regulating their emotions.
Development of PTSD therapies based on biomarkers
About 250 million people worldwide live with PTSD, but there are no treatments and they often cause many side effects that can last a lifetime. Prism for PTSD, GMH’s first offering is in clinical research in five locations in the United States and Israel, with the potential to serve as a complement to standard care therapy. Prism helps patients regain the ability to control their emotions. Prism is a non-invasive complementary digital therapy that uses new biomarkers based on neuroscience and specific to the brain mechanism. GMH is the first to use machine learning technology to create an electrical fingerprint (VET) of brain-specific biomarkers used in its patented treatment of mental disorders, training patients to use self-modulation techniques using a interactive system. audiovisual software.
By fusing the electroencephalogram and functional magnetic resonance imaging data, Prism for PTSD produces a continuous, real-time, accessible amygdala-EFP biomarker. During treatment sessions, an audiovisual interface responds as patients use self-neuromodulation techniques to down-regulate their amygdala-VET biomarker. The company plans to evaluate the clinical efficacy and safety of Prism for additional indications of mental disorder, such as MDD, Attention Deficit Hyperactivity Disorder, General Anxiety Disorder, Obsessive Compulsive Disorder, and Borderline Personality Disorder .
“GrayMatters is introducing the first digital therapeutic device that directly targets and regulates specific brain biomarkers associated with mental disorders, while the digitization of existing therapy methods focuses on mitigating the resulting symptoms and behaviors,” said co-founder Oded Kraft and CEO of GrayMatters Health. “This round of funding will help GrayMatters Health complete its clinical research, obtain regulatory approval, and launch Prism for PTSD in the United States. It also supports our collaboration with McLean Hospital, the psychiatric subsidiary. “We are planning to conduct clinical research to determine the effectiveness and safety of Prism as an adjunctive treatment for Major Depressive Disorder (MDD) with anedonia.”